The UK’s medicines and medical devices regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), has formed a partnership with Manchester University NHS Trust to create a health innovation “sandbox” that will trial new technologies in routine NHS care.
What the programme will do
The initiative, called Manchester Sandbox, aims to accelerate evaluation of technologies that could improve diagnosis, personalise care and relieve pressure on health services. The first programme will deploy promising innovations — including AI‑enabled tools — in local NHS settings to collect real‑world evidence on how they perform with patients and clinicians.
According to the trust’s chief executive, the partnership seeks to balance rapid access to innovation with patient safety. The MHRA said engagement between regulators, providers and developers earlier in the product pathway is central to understanding where technologies can make the biggest difference.
“Patients should benefit from innovation as quickly as possible, but they should never have to choose between access and safety,”
The scheme will invite expressions of interest from device developers and plans to test, among other tools, an AI application designed to identify patients at higher risk of complications from long‑term conditions.
Why this matters to health systems
Health regulators and hospital systems often face a tension: innovations reach promising results in development, but their real value and risks only become evident when used in everyday clinical workflows. The sandbox approach aims to close that evidence gap by:
- testing technologies in live clinical environments rather than only in laboratory settings;
- bringing regulators into the evaluation process earlier so safety and compliance issues are identified promptly;
- gathering practical data on how tools interact with clinicians, patients and existing IT systems.
For health services, this could mean faster, more confident adoption of solutions that demonstrably reduce harm, improve outcomes or ease workforce workload — while reducing the likelihood of widescale roll‑out of poorly performing products.
Potential benefits and limits
Proponents argue that sandbox models can shorten the route from innovation to safe deployment. The MHRA emphasised the need to understand how technologies function in practice and where they deliver greatest benefit. Manchester Trust leaders highlighted that the approach can help patients gain earlier access to useful developments without compromising safety standards.
At the same time, sandbox evaluations are not a panacea. Evidence generated within one health system and local patient population may not automatically translate to another setting. Differences in clinical pathways, workforce capacity, digital infrastructure and regulatory environments mean findings should be interpreted with caution when transferred across borders.
| Sandbox objective | Expected outcome |
|---|---|
| Real‑world testing of innovations | Evidence on performance with patients and clinicians |
| Earlier regulator‑provider collaboration | Faster identification of safety and compliance issues |
| Focused programmes (eg, AI risk‑stratification) | Targeted insights for clinical integration |
For South African policymakers and hospital managers, the Manchester Sandbox provides a model for structured evaluation of digital and device innovations. It underscores the value of regulatory involvement during piloting and the need for robust local evidence before scale‑up.
Readers are reminded that new technologies should be discussed with treating clinicians and that trial results in one jurisdiction may not predict outcomes locally. Clinicians and health managers considering adoption should seek detailed evidence and regulatory guidance tailored to their setting.
